Owkin, a French-American biotechnology company that applies artificial intelligence (AI) to drug discovery, development and diagnostics, announced that it has entered into a collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to develop and commercialize AI-powered digital pathology diagnostics for the EU market.